XLR-12

XLR-12
Legal status
Legal status	CA: Schedule II;
Identifiers
	IUPAC name (2,2,3,3-Tetramethylcyclopropyl)[1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]methanone;
CAS Number	895155-78-9 ;
PubChem CID	11559386;
ChemSpider	9734160;
UNII	EG79K9XQF5;
CompTox Dashboard (EPA)	DTXSID201024738 ;
Chemical and physical data
Formula	C20H24F3NO
Molar mass	351.413 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C1C(C1(C)C)(C)C)c1cn(c2c1cccc2)CCCC(F)(F)F;
	InChI InChI=1S/C20H24F3NO/c1-18(2)17(19(18,3)4)16(25)14-12-24(11-7-10-20(21,22)23)15-9-6-5-8-13(14)15/h5-6,8-9,12,17H,7,10-11H2,1-4H3; Key:PEXYKZYTXIEEOB-UHFFFAOYSA-N;

XLR-12 is an indole-based synthetic cannabinoid drug that was invented by Abbott Laboratories in 2006.^[1] It is an analogue of XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB₂ receptor, with a K_i of 0.09 nM and 167x selectivity over the related CB₁ receptor, however it still retains appreciable affinity for CB₁ with a K_i of 15 nM.^[2]